Glycopeptide-Based Antibody Detection in Multiple Sclerosis by Surface Plasmon Resonance

Sensors

Feliciana Real-Fernández²  Irene Passalacqua²  Elisa Peroni¹  Mario Chelli²  Francesco Lolli²  Anna Maria Papini² 

[1] Laboratoire SOSCO EA 4505, University of Cergy-Pontoise, 5 mail Gay-Lussac, Neuville sur Oise, Cergy-Pontoise cedex 95031, France; E-Mail:;Laboratory of Peptide & Protein Chemistry & Biology, Polo Scientifico e Tecnologico, University of Florence; I-50019 Sesto Fiorentino (FI), Italy; E-Mails:

关键词: multiple sclerosis;    surface plasmon resonance;    serodiagnosis;    biacore;    immunoassay;    glycopeptide CSF114(Glc);   

DOI  :  10.3390/s120505596

来源: mdpi

【 摘 要 】

In multiple sclerosis (MS) the gold standard for the diagnosis and prognosis is, up to now, the use of magnetic resonance imaging markers. No alternative simpler assays proven of use, except for cerebrospinal fluid analysis, have been provided in MS diagnosis. Therefore, there is a need to develop non-invasive, sensitive, simple new techniques for the clinical routine. Herein we present the evaluation of the feasibility of a glycopeptide-based biosensor to detect MS specific antibodies in sera using the surface plasmon resonance technology. The previously described glycopeptide antigen CSF114(Glc) has been immobilized on a gold sensor chip and the method has been optimized for real-time specific autoantibody detection directly in sera. A population of 60 healthy blood donors and 61 multiple sclerosis patients has been screened. The receiver operating characteristic (ROC)-based analysis has established the optimal diagnostic cut-off value for the method obtaining a sensitivity of 36% and a specificity of 95%. Sample sera have been also screened with a previously validated ELISA.

【 授权许可】

CC BY   
© 2012 by the authors; licensee MDPI, Basel, Switzerland